Your browser doesn't support javascript.
loading
Oral ribavirin for paramyxovirus infection after alemtuzumab-containing reduced-intensity conditioning HCT regimen.
Dreyzin, Alexandra; Michaels, Marian G; Vander Lugt, Mark T; Szabolcs, Paul.
Afiliação
  • Dreyzin A; Department of Pediatrics, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania.
  • Michaels MG; Department of Pediatrics, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania.
  • Vander Lugt MT; Division of Infectious Disease, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania.
  • Szabolcs P; Blood and Marrow Transplant Program, Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, Michigan.
Pediatr Transplant ; 23(2): e13358, 2019 03.
Article em En | MEDLINE | ID: mdl-30687992

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Ribavirina / Infecções por Paramyxoviridae / Transplante de Células-Tronco Hematopoéticas / Condicionamento Pré-Transplante / Alemtuzumab / Imunossupressores Limite: Adult / Child / Humans / Infant / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Ribavirina / Infecções por Paramyxoviridae / Transplante de Células-Tronco Hematopoéticas / Condicionamento Pré-Transplante / Alemtuzumab / Imunossupressores Limite: Adult / Child / Humans / Infant / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article